Point72 Asset Management’s TetraLogic Pharmaceuticals Corporation TLOG Stock Holding History

Point72 Asset Management’s Portfolio TLOG Stock Details TLOG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-125,559	Closed	-$550K	–	936
2015 Q1	$550K	Buy	125,559 +26,089	+26%	+$131K	﹤0.01%	640
2014 Q4	$479K	Buy	+99,470	New	+$445K	﹤0.01%	615

Other funds holding TLOG

Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

FWC

First Washington Corp Seattle, Washington $353M AUM 41.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CCA

Catalyst Capital Advisors Huntington, New York $6.03B AUM 24.5% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Point72 Asset Management's TLOG Position: Q2 2015 in Review

Point72 Asset Management sold out of TetraLogic Pharmaceuticals Corporation (TLOG) in Q2 2015, closing a stake of 125,559 shares — an estimated $550K sold.

Point72 Asset Management first reported a position in TLOG in Q4 2014 and held it in 2 quarters. The position peaked at $550K in Q1 2015. 33 funds tracked by Wall St. Rank hold TLOG as of Q2 2015.

Point72 Asset Management reported no remaining TetraLogic Pharmaceuticals Corporation position as of Q2 2015 after selling out during the quarter.
Point72 Asset Management sold 125,559 TetraLogic Pharmaceuticals Corporation shares in Q2 2015, an estimated $550K.
Point72 Asset Management first reported a position in TetraLogic Pharmaceuticals Corporation in Q4 2014 and held it in 2 quarters.
Point72 Asset Management's TetraLogic Pharmaceuticals Corporation position peaked at $550K in Q1 2015.
33 funds tracked by Wall St. Rank held TetraLogic Pharmaceuticals Corporation as of Q2 2015.

Based on Point72 Asset Management's 13F filing for Q2 2015, filed 14 Aug 2015.